A Statue Gets a Fresh Coat of Paint: A Glimpse at the Catholic Church and Chicano Activists in the Rio Grande Valley in 1970

In December, 1969, at the end of a weekend conference, a group of Mexican American activist students painted a statue of Mary brown, causing an uproar among some priests and faithful. This reaction did not, however, cause the Church to pull back on its commitment to social justice. Indeed, some bishops, priests, and laity took strong positions and acted on issues related to farmworkers and Chicano youth projects in the face of opposition within the Church and among the public. This paper utilizes oral history interviews, newspaper accounts, and documents in archives of the Oblate School of Theolog

Laredo, Texas: Gateway Community on the Texas Borderlands, Archaeological and Historical Investigations for the Laredo City Toll Plaza

In July 1980, the Center for Archaeological Research, The University of Texas at San Antonio, conducted archaeological and historical investigations at sites designated as 41 WB 36,41 WB 37, and 41 WB 38, which are located in a residential district on the east side of the town of Laredo, Texas. These sites are represented by late historic foundations which were uncovered after a group of houses were razed to make way for a new toll bridge complex to facilitate international travel between the United States and the Republic of Mexico. A short history of Laredo and of the four house foundations excavated by the Center for Archaeological Research is presented in this report. The archaeological investigations of the structures and their associated artifacts are described and interpreted to provide a better understanding of sociocultural activities in Laredo from early historic times to the present

Reemergence of Dengue in Southern Texas, 2013

During a dengue epidemic in northern Mexico, enhanced surveillance identified 53 laboratory-positive cases in southern Texas; 26 (49%) patients acquired the infection locally, and 29 (55%) were hospitalized. Of 83 patient specimens that were initially IgM negative according to ELISA performed at a commercial laboratory, 14 (17%) were dengue virus positive by real-time reverse transcription PCR performed at the Centers for Disease Control and Prevention. Dengue virus types 1 and 3 were identified, and molecular phylogenetic analysis demonstrated close identity with viruses that had recently circulated in Mexico and Central America. Of 51 household members of 22 dengue case-patients who participated in household investigations, 6 (12%) had been recently infected with a dengue virus and reported no recent travel, suggesting intrahousehold transmission. One household member reported having a recent illness consistent with dengue. This outbreak reinforces emergence of dengue in southern Texas, particularly when incidence is high in northern Mexico

Risk of COVID-19 after natural infection or vaccinationResearch in context

Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health